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−42%/−44% when centres were grouped by the number of A-AF procedures per-
formed. Total cost of A-AF (including 2 years post-procedure follow-up) was c10,163 
(m-mat) or c9,632 (m-geo). Cost of follow-up represented only 8% on total cost of 
A-AF. CONCLUSIONS: The cost of AF ablation procedures is signiﬁ cant and is 
largely under-funded by the DRG tariff, which showed inadequate to remunerate 
hospitals in all Italian Regions.
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OBJECTIVES: TAVI is a novel interventional procedure and is considered as an 
alternative to surgery in high risk patients with severe aortic stenosis. For commis-
sioning purposes, a cost consequences model was derived to look at the impact of 
substituting TAVI for high risk conventional surgery patients. METHODS: The cost 
consequence included hospital LOS on CITU, HDU and ward and pacemakers implan-
tation costs. Twenty-ﬁ ve patients were retrospectively identiﬁ ed by clinicans with 
TAVI experience who might have been eligible to receive TAVI in the previous year 
of introduction of TAVI on the market. The patient speciﬁ cation was aligned with the 
TAVI device CE marking criteria. The average TAVI patient cost was obtained from 
a manufacturer sponsored economic model which used UK patient level data from 
their sponsored registry. The hospital’s local database was used for unit costs. Costs 
were calculated based on mean values for CITU (critical intensive care unit), HDU 
(high dependency unit), ward and pacemaker implantation. We also calculated the 
mean cost per case based on the total length of stay (LOS) for CITU, HDU ward and 
pacemaker implants of each of the isolated AVR and AVR plus valvular disease (AVR 
+ CABG) population. RESULTS: The total cost based on mean LOS values was 
£21,460 for isolated AVR and £23,032 for AVR + CABG. The cost per TAVI case 
based on total LOS was £24,721 compared to £49,982 for AVR + CABG. CONCLU-
SIONS: The cost consequence model was sensitive to long LOS on CITU and HDU 
in the AVR plus CABG group. Using a cost consequences model TAVI was at worst 
cost neutral and at best most likely to deliver substantial savings in this centre in this 
well deﬁ ned patient population. This ﬁ nding is signiﬁ cant in assessment of the “real” 
cost impact for substituting TAVI for high risk conventional surgery.
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OBJECTIVES: Chronic heart failure (CHF) is associated with poor quality of life 
resulting from physical and psycho-social limitations. The FAIR-HF trial showed 
clinical and quality of life beneﬁ ts of iron deﬁ ciency treatment in CHF patients using 
ferric carboxymaltose (FCM), an intravenous (i.v.) iron preparation. This study evalu-
ated the cost-effectiveness of iron repletion using FCM in CHF patients, from the 
perspectives of the statutory health insurance (Germany) and the National Health 
Service (UK). METHODS: Using data from FAIR-HF, a randomized, double-blind, 
controlled clinical trial (n = 459), per-patient costs and clinical effectiveness of FCM 
were estimated. Economic assessment was based on published costs associated with 
New York Heart Association (NYHA) functional classes. Effectiveness was assessed 
as the number of QALYs gained, derived from EQ-5D scores. The ICER of FCM was 
determined compared to placebo. Time horizon of this within-trial analysis was 24 
weeks. RESULTS: In the FAIR-HF trial, NYHA classes were signiﬁ cantly improved 
in the FCM group compared with placebo (P < 0.001). Estimated per-patient costs 
(excluding iron costs) were c2625 and c2919 (Germany), and £4155 and £4621 (UK), 
for FCM and placebo arms, respectively. Based on the reimbursed price for FCM in 
Germany and UK (c28 and £19 per 100 mg iron) and the mean iron dosage of the 
clinical study (1850 mg) plus administration costs, a net investment of c530 and £68 
per patient would be required. FCM resulted in an estimated gain of 0.0254 QALYs 
over the study period. The ICER of FCM ranged from c20,872 to £2,682 per QALY 
gained for the FAIR-HF dosing regimen, compared to placebo. ICER-differences result 
from disparities in administration and medication costs. CONCLUSIONS: From the 
German and UK payers’ perspective, managing iron deﬁ ciency in CHF patients using 
i.v. FCM can be considered cost-effective. Improved symptoms and better quality of 
life contribute to economic beneﬁ ts seen with FCM.
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OBJECTIVES: To estimate cost/effectiveness and cost/utility of dabigatran etexilate 
(DBG) compared to standard care for the prevention of venous thromboembolism 
(VTE) secondary to total hip replacement (THR) or total knee replacement (TKR) in 
Italy. METHODS: A decision analytic, Markov-chain based model originally devel-
oped for the UK has been adapted to the Italian context. Clinical outcomes, including 
incidences of VTE and treatment-related adverse events, were extrapolated from head-
to-head, phase III trials of DBG vs. enoxaparin. For the other low molecular weight 
heparins (LMWHs), indirect comparisons were performed on the basis of equal 
effectiveness assumptions. The adaptation involved cost and demographic character-
istics, leaving clinical and utility data unvaried. Costs are taken from national obser-
vational studies, where available. Otherwise, current prices and tariffs are applied. 
Resources consumption where derived from practice guidelines or taken from those 
estimated for the UK model. According to the prevalent national practice, extended 
prophylaxis has been considered for both surgical procedures. Time horizon of the 
analysis is patients’ lifetime. RESULTS: Compared to LMWHs, DBG is associated to 
an expected increase of 0.019 LYs and 0.014 QALYs per THR patient and of 0.024 
LYs and 0.019 QALYs per TKR patient. DBG-related cost is lower than competitors 
in both procedures, with a mean difference ranging between c82 and c109 for THR, 
and 100 and 135 for TKR, depending on the considered comparator. Higher acquisi-
tion costs for DBG are completely offset and inverted by avoided administration 
expenses and, less importantly, by savings on VTE management. Probabilistic sensitiv-
ity analysis estimates that, for a willingness to pay threshold of £30,000 (~c33,500)/
QALY, DBG is associated to a probability of being cost/effective of about 98% for 
THR and of 90% for TKR. CONCLUSIONS: On average DBG dominates LMWHs, 
as it’s expected to be cost-saving and non-inferior in terms of efﬁ cacy and safety.
PCV67
COST-EFFECTIVENESS OF FONDAPARINUX VS. ENOXAPARIN IN 
NON-ST-ELEVATION ACUTE CORONARY SYNDROMES IN RUSSIA
Vorobyev PA1, Borisenko O1, Lesnicheva M1, Shiganov S2, Lomakin A3
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia; 2Abakan 
City Hospital, Abakan, Russia; 3GlaxoSmithKline Russia, Moscow, Russia
OBJECTIVES: To assess cost-effectiveness of fondaparinux versus enoxaparin in 
patients with non-ST-elevation acute coronary syndrome in Russia. METHODS: A 
decision tree model was created incorporating the outcomes associated with 2 anti-
thrombotic approaches from OASIS-5 trial: enoxaparin (1 mg/kg every 12 hours) 
versus fondaparinux (2.5 mg/day). Probabilities of complications (e.g., myocardial 
infarction, stroke, major bleeding at 9, 30 and 180 days) were calculated. Data on 
resource utilization (staff, drugs, materials, laboratory, and equipment), diagnosis and 
treatment came from the hospital survey. Resources were valued in internal hospital 
prices based on obligatory medical insurance tariffs (as of 2008). The incremental 
cost-effectiveness ratio for fondaparinux per death avoided and per major bleeding 
episode avoided versus enoxaparin was quantiﬁed. Sensitivity analysis was performed. 
RESULTS: The cost analysis showed that fondaparinux would generate a cost saving 
of 1634 RUR (c43), 1902 RUR (c50) and 2167 RUR (c57) per patient at 9, 30 and 
180 days respectively. When cost and clinical results were extrapolated to cost-
effectiveness, fondaparinux was dominant (less costly and more effective in terms of 
death avoided and major bleeding episode avoided). The sensitivity analysis proved 
that costs of pharmacotherapy with fondaparinux and enoxaparin had the biggest 
impact on results. CONCLUSIONS: Fondaparinux is a more cost-effective option 
than enoxaparin in treatment of patients with non-ST-elevation acute coronary syn-
drome from the hospital perspective in Russia.
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OBJECTIVES: The Framingham Risk Score is a well-accepted tool to estimate the 
10-year risk of developing coronary heart disease (CHD). However, many patients 
fall into the intermediate risk category. Improved discrimination within this category 
is necessary to prevent CHD and side-effects of statins therapy efﬁ ciently. This eco-
nomic evaluation calculated the potential lifetime cost-effectiveness of a novel bio-
marker test which helps to decide whether patients with an intermediate risk should 
be treated with statins. METHODS: Prognosis of patients with an intermediate risk 
was simulated with a Markov chain Monte Carlo model to estimate the potential 
lifetime costs and effects (life-years (LY)) for three strategies: treat all with statins, 
treat none with statins or use a test to select patients for statin treatment. Costs were 
calculated for the The Netherlands using a health care sector perspective. Values for 
all input parameter were derived from the literature. RESULTS: A strategy using a 
perfect test for a 55-year old man would be slightly more expensive than the treat-none 
option (c1966 vs. c1941) but less expensive than the treat-all option (c5374). The test 
and the treat-all option would be equally effective (24.45 LY) and more effective than 
the treat-none option (24.3 LY). An ICER of c170 versus treat-none indicates that it 
is a biomarker test with great potential. Results were sensitive to uncertainties regard-
ing model parameters such as the sensitivity, speciﬁ city and costs of the test, as well 
as CHD risk, and the costs and effectiveness of statins. CONCLUSIONS: A test to 
reclassify patients in the Framingham intermediate risk group into higher and lower 
risk categories has the potential to optimize cost-effectiveness by preventing CHD and 
reduce the risk of drug side-effects. Values used in this model (e.g., test sensitivity and 
speciﬁ city) can be adjusted wherever needed to determine whether continued develop-
ment of a biomarker is worthwhile.
